FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382653433> ?p ?o ?g. }

• W4382653433 abstract "Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood and tissue eosinophilia. Objective To assess the effectiveness and safety of mepolizumab (anti-IL-5) and benralizumab (anti-IL-5Rα) in EGPA for 24 months. Methods We conducted a multicenter observational study, including patients with EGPA treated with anti-IL-5/Rα biologics in 9 Italian specialized facilities. Systemic disease activity, remission and relapse rate were evaluated from 3 to 24 months after treatment initiation. Respiratory outcomes, hematological parameters, corticosteroid (OCS) and immunosuppressants consumption were also assessed. Results 49 patients with relapsing-refractory EGPA were included [26 (53.1%) benralizumab 30mg, 20 (40.8%) mepolizumab 100mg, 3 (6.1%) mepolizumab 300mg]. Overall, 38.8% and 57.1% achieved remission after 12 and 24 months, respectively (69.2% benralizumab and 43.5% mepolizumab). Lower OCS intake and higher blood eosinophil count at baseline were associated with remission at 24 months. Both biologics exerted beneficial effects on severe asthma outcomes. Indeed, 61.2% (61.5% benralizumab and 60.8% mepolizumab) remained exacerbation-free during treatment. Lung function parameters showed improvements in the overall cohort (all p&lt; 0.05), but began to decline from month 12, especially with mepolizumab. Marked reduction in blood eosinophils was registered with mepolizumab ( p&lt; 0.0001), while benralizumab depleted both eosinophils ( p&lt; 0.0001) and basophils ( p &lt;0.0001). In general, 69.6% (76% benralizumab and 61.9% mepolizumab) of OCS-dependent patients lowered their daily dose by 75%, while 28.3% discontinued these drugs. Immunosuppressants were suspended in 88.2% of cases. Adverse events were reported in 8.2% of patients. Conclusions These real-world data suggest that anti-IL-5/Rα biologics are effective and safe in the long-term as add-on treatments for patients with EGPA." @default.
• W4382653433 created "2023-07-01" @default.
• W4382653433 creator A5001116765 @default.
• W4382653433 creator A5004648556 @default.
• W4382653433 creator A5008755507 @default.
• W4382653433 creator A5014181660 @default.
• W4382653433 creator A5022962935 @default.
• W4382653433 creator A5024276000 @default.
• W4382653433 creator A5024772834 @default.
• W4382653433 creator A5027824133 @default.
• W4382653433 creator A5028306950 @default.
• W4382653433 creator A5028894579 @default.
• W4382653433 creator A5032460602 @default.
• W4382653433 creator A5036474739 @default.
• W4382653433 creator A5040451669 @default.
• W4382653433 creator A5049355810 @default.
• W4382653433 creator A5058199035 @default.
• W4382653433 creator A5061920107 @default.
• W4382653433 creator A5066157738 @default.
• W4382653433 creator A5074345615 @default.
• W4382653433 creator A5088550336 @default.
• W4382653433 date "2023-06-30" @default.
• W4382653433 modified "2023-09-25" @default.
• W4382653433 title "Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study" @default.
• W4382653433 cites W174387549 @default.
• W4382653433 cites W2024564671 @default.
• W4382653433 cites W2053251763 @default.
• W4382653433 cites W2064940997 @default.
• W4382653433 cites W2071333258 @default.
• W4382653433 cites W2075699130 @default.
• W4382653433 cites W2097446240 @default.
• W4382653433 cites W2098276532 @default.
• W4382653433 cites W2106779701 @default.
• W4382653433 cites W2115453427 @default.
• W4382653433 cites W2120427700 @default.
• W4382653433 cites W2125078269 @default.
• W4382653433 cites W2138355864 @default.
• W4382653433 cites W2150534327 @default.
• W4382653433 cites W2156511362 @default.
• W4382653433 cites W2288102166 @default.
• W4382653433 cites W2513258422 @default.
• W4382653433 cites W2601675613 @default.
• W4382653433 cites W2615817830 @default.
• W4382653433 cites W2616424562 @default.
• W4382653433 cites W2753423724 @default.
• W4382653433 cites W2765228582 @default.
• W4382653433 cites W2791261363 @default.
• W4382653433 cites W3017503864 @default.
• W4382653433 cites W3025657704 @default.
• W4382653433 cites W3033040959 @default.
• W4382653433 cites W3036852310 @default.
• W4382653433 cites W3087006406 @default.
• W4382653433 cites W3090710509 @default.
• W4382653433 cites W3091802486 @default.
• W4382653433 cites W3093467193 @default.
• W4382653433 cites W3130012184 @default.
• W4382653433 cites W3168769441 @default.
• W4382653433 cites W3174068072 @default.
• W4382653433 cites W3175304472 @default.
• W4382653433 cites W3179134980 @default.
• W4382653433 cites W3192465273 @default.
• W4382653433 cites W3194122667 @default.
• W4382653433 cites W3204022974 @default.
• W4382653433 cites W4200037359 @default.
• W4382653433 cites W4210473552 @default.
• W4382653433 cites W4220654091 @default.
• W4382653433 cites W4220729298 @default.
• W4382653433 cites W4224282077 @default.
• W4382653433 cites W4307155457 @default.
• W4382653433 cites W4376114466 @default.
• W4382653433 doi "https://doi.org/10.3389/fimmu.2023.1204444" @default.
• W4382653433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37457743" @default.
• W4382653433 hasPublicationYear "2023" @default.
• W4382653433 type Work @default.
• W4382653433 citedByCount "0" @default.
• W4382653433 crossrefType "journal-article" @default.
• W4382653433 hasAuthorship W4382653433A5001116765 @default.
• W4382653433 hasAuthorship W4382653433A5004648556 @default.
• W4382653433 hasAuthorship W4382653433A5008755507 @default.
• W4382653433 hasAuthorship W4382653433A5014181660 @default.
• W4382653433 hasAuthorship W4382653433A5022962935 @default.
• W4382653433 hasAuthorship W4382653433A5024276000 @default.
• W4382653433 hasAuthorship W4382653433A5024772834 @default.
• W4382653433 hasAuthorship W4382653433A5027824133 @default.
• W4382653433 hasAuthorship W4382653433A5028306950 @default.
• W4382653433 hasAuthorship W4382653433A5028894579 @default.
• W4382653433 hasAuthorship W4382653433A5032460602 @default.
• W4382653433 hasAuthorship W4382653433A5036474739 @default.
• W4382653433 hasAuthorship W4382653433A5040451669 @default.
• W4382653433 hasAuthorship W4382653433A5049355810 @default.
• W4382653433 hasAuthorship W4382653433A5058199035 @default.
• W4382653433 hasAuthorship W4382653433A5061920107 @default.
• W4382653433 hasAuthorship W4382653433A5066157738 @default.
• W4382653433 hasAuthorship W4382653433A5074345615 @default.
• W4382653433 hasAuthorship W4382653433A5088550336 @default.
• W4382653433 hasBestOaLocation W43826534331 @default.
• W4382653433 hasConcept C126322002 @default.
• W4382653433 hasConcept C197934379 @default.
• W4382653433 hasConcept C203014093 @default.
• W4382653433 hasConcept C2776015282 @default.

• next